Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 1,173.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 175,875 shares of the biopharmaceutical company’s stock after purchasing an additional 162,068 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Dynavax Technologies were worth $760,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. California Public Employees Retirement System raised its stake in shares of Dynavax Technologies by 29.9% in the third quarter. California Public Employees Retirement System now owns 240,442 shares of the biopharmaceutical company’s stock valued at $1,039,000 after acquiring an additional 55,324 shares during the period. Wells Fargo & Company MN raised its stake in shares of Dynavax Technologies by 4.8% in the third quarter. Wells Fargo & Company MN now owns 205,336 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 9,325 shares during the period. American International Group Inc. raised its stake in shares of Dynavax Technologies by 16.2% in the third quarter. American International Group Inc. now owns 63,535 shares of the biopharmaceutical company’s stock valued at $275,000 after acquiring an additional 8,837 shares during the period. Raymond James Financial Services Advisors Inc. purchased a new position in Dynavax Technologies in the 3rd quarter worth about $45,000. Finally, BNP Paribas Arbitrage SA increased its stake in Dynavax Technologies by 112.0% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 25,216 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 13,320 shares during the period. 77.16% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:DVAX opened at $4.42 on Friday. Dynavax Technologies Co. has a 52 week low of $1.80 and a 52 week high of $12.44. The company has a quick ratio of 3.47, a current ratio of 4.35 and a debt-to-equity ratio of 2.59. The stock has a market capitalization of $486.97 million, a PE ratio of -3.23 and a beta of 1.16. The stock’s 50-day moving average price is $4.24 and its 200-day moving average price is $6.03.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. Dynavax Technologies had a negative return on equity of 193.85% and a negative net margin of 256.92%. Sell-side analysts expect that Dynavax Technologies Co. will post -0.7 earnings per share for the current fiscal year.

DVAX has been the topic of several recent analyst reports. BidaskClub downgraded shares of Dynavax Technologies from a “sell” rating to a “strong sell” rating in a research note on Friday, September 4th. ValuEngine raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, November 2nd. Zacks Investment Research downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, November 11th. Finally, HC Wainwright increased their target price on shares of Dynavax Technologies from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Dynavax Technologies currently has an average rating of “Hold” and a consensus price target of $14.38.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older.

Featured Article: Buy-Side Analysts

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.